Meredith O. Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meredith O. Cruz has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Joan Briller
Division of Cardiology, Department of Medicine, Department of Obstetrics and Gynecology, University of Illinois, Chicago, IL 60612, USA
2 shared publications- Judith Hibbard
Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
2 shared publications - Alina Tvina
Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, Wisconsin
1 shared publication - Anna Palatnik
Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
1 shared publication Donald A. PT Neumann
Marquette University, Milwaukee, Wisconsin
1 shared publication- Emily R. Smith
Division of Maternal-Fetal Medicine, Department of Obstetrics, Penn State College of Medicine, Penn State Health, Milton S. Hershey Medical Center, Hershey, USA
1 shared publication
Latest Publications
- 18 July 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 52 (3)
Obstetric Medicine in the Modern Era: Managing High-Risk Pregnancies
- 18 July 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 52 (3)
Obstetric Medicine in the Modern Era: Managing High-Risk Pregnancies
- 15 July 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 52 (3) , 445-456
Cardiac Considerations in Pregnancy: A Spotlight on Peripartum Cardiomyopathy and Pregnancy-Associated Spontaneous Coronary Dissection
- 15 July 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 52 (3) , 445-456
Cardiac Considerations in Pregnancy: A Spotlight on Peripartum Cardiomyopathy and Pregnancy-Associated Spontaneous Coronary Dissection
- Open Access
- 2 May 2023
- Published by Hindawi Limited in Case Reports in Obstetrics and Gynecology
- Vol. 2023, 1-4
Cervical Ripening Balloon in Combination with Methotrexate and Potassium Chloride for the Treatment of a 13-week Cervical Ectopic Pregnancy
Background. Cervical pregnancy, an uncommon type of ectopic pregnancy, can lead to devastating consequences if not diagnosed and treated early. Despite this, there are no specific guidelines on how to treat such pregnancies especially in advanced gestational ages (GAs). Case. This is a 35-year-old patient who presented to our hospital at 13 weeks GA after failing systemic multidose methotrexate therapy for a cervical ectopic pregnancy. Given desire to preserve fertility, a minimally invasive conservative approach was taken involving potassium chloride (KCl) and methotrexate injections into the gestational sac, followed by immediate Cook intracervical double balloon placement under direct ultrasound visualization, with removal of the balloon after 72 hours, and ultimately resolution of the pregnancy 12 weeks after the removal. Conclusion. Advanced first trimester cervical ectopic pregnancy after failure of methotrexate therapy was managed successfully with minimally invasive KCl and methotrexate injections in combination with cervical ripening balloon.
- 2 May 2023
- Published by Hindawi Limited in Case Reports in Obstetrics and Gynecology
- Vol. 2023, 1-4
Open AccessCervical Ripening Balloon in Combination with Methotrexate and Potassium Chloride for the Treatment of a 13-week Cervical Ectopic Pregnancy
Background. Cervical pregnancy, an uncommon type of ectopic pregnancy, can lead to devastating consequences if not diagnosed and treated early. Despite this, there are no specific guidelines on how to treat such pregnancies especially in advanced gestational ages (GAs). Case. This is a 35-year-old patient who presented to our hospital at 13 weeks GA after failing systemic multidose methotrexate therapy for a cervical ectopic pregnancy. Given desire to preserve fertility, a minimally invasive conservative approach was taken involving potassium chloride (KCl) and methotrexate injections into the gestational sac, followed by immediate Cook intracervical double balloon placement under direct ultrasound visualization, with removal of the balloon after 72 hours, and ultimately resolution of the pregnancy 12 weeks after the removal. Conclusion. Advanced first trimester cervical ectopic pregnancy after failure of methotrexate therapy was managed successfully with minimally invasive KCl and methotrexate injections in combination with cervical ripening balloon.
- Open Access
O -GlcNAc transferase contributes to sex-specific placental deregulation in gestational diabetes
Fetal sex has been known to be associated with differential risks for adverse perinatal outcomes. Recently it has been highlighted as a risk factor for gestational diabetes (GDM), which carries short- and long-term cardiometabolic implications for the pregnant women and their offspring. Understanding the molecular mechanisms through which fetal sex can modulate placenta physiology can help identify novel molecular targets for future clinical applications. In this study, we investigated the nutrient-sensing O -GlcNAc pathway as a potential mediator of sex-driven placenta dysfunction due to the unique location of the O -GlcNAc transferase (OGT) enzyme on the X chromosome. Using banked placenta tissues, we demonstrated that placenta OGT is downregulated in women with GDM, especially when carrying a male offspring. We modeled our observation in vitro using male placenta trophoblast BeWo cells in which OGT was knocked down. A comprehensive transcriptomic profile via RNA sequencing demonstrated changes in hormonal, inflammatory and immunologic markers, toward GDM-like transcriptional signatures. Altogether, this study suggests that OGT deserves important consideration for sexual dimorphism observed in GDM and highlights the importance of O-GlcNAcylation in placenta endocrine physiology.
Open AccessO -GlcNAc transferase contributes to sex-specific placental deregulation in gestational diabetes
Fetal sex has been known to be associated with differential risks for adverse perinatal outcomes. Recently it has been highlighted as a risk factor for gestational diabetes (GDM), which carries short- and long-term cardiometabolic implications for the pregnant women and their offspring. Understanding the molecular mechanisms through which fetal sex can modulate placenta physiology can help identify novel molecular targets for future clinical applications. In this study, we investigated the nutrient-sensing O -GlcNAc pathway as a potential mediator of sex-driven placenta dysfunction due to the unique location of the O -GlcNAc transferase (OGT) enzyme on the X chromosome. Using banked placenta tissues, we demonstrated that placenta OGT is downregulated in women with GDM, especially when carrying a male offspring. We modeled our observation in vitro using male placenta trophoblast BeWo cells in which OGT was knocked down. A comprehensive transcriptomic profile via RNA sequencing demonstrated changes in hormonal, inflammatory and immunologic markers, toward GDM-like transcriptional signatures. Altogether, this study suggests that OGT deserves important consideration for sexual dimorphism observed in GDM and highlights the importance of O-GlcNAcylation in placenta endocrine physiology.
- 1 June 2018
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 45 (2) , 281-298
New Insights in Peripartum Cardiomyopathy
- 1 June 2018
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 45 (2) , 281-298
New Insights in Peripartum Cardiomyopathy
- Open Access
- 1 January 2018
- Published by Wolters Kluwer Health in Journal of Women's Health Physical Therapy
- Vol. 42 (3) , 128-138
Fatigability of the Lumbopelvic Stabilizing Muscles in Women 8 and 26 Weeks Postpartum
Background: Pregnancy and childbirth are associated with lumbopelvic pain and instability. Fatigability of the lumbopelvic stabilizing muscles after childbirth is unknown, and no clinical tests exist to assess this important metric of muscle function. Objectives: To compare fatigability of the lumbopelvic stabilizing muscles in postpartum and nulligravid (control) women using the Active Straight Leg Raise (ASLR) Fatigue Task, and to determine whether fatigability is associated with interrecti distance (IRD), physical function, and pain/disability. Study design: A longitudinal case-control study. Methods: Twenty-nine nulligravid (25.4 ± 9.1 years) and 31 postpartum women (31.4 ± 5.2 years; vaginal delivery n = 18) were tested at 2 time points, 16 weeks apart (postpartum women tested at 8-10 and 24-26 weeks postpartum). Muscular function was assessed with manual muscle testing (MMT), the ASLR test, and a new ASLR Fatigue Task. Other measures included IRD, rectus abdominis thickness, physical activity, and 6-minute walk distance. Results: Postpartum women were 23% more fatigable (P = .028) and were weaker (MMT) (P < .001) than controls up to 26 weeks postpartum. The ASLR Fatigue Task (time-to-failure) was associated with smaller IRD, greater rectus abdominis thickness, higher physical activity levels, greater MMT strength, and further distance walked in 6 minutes (P < .05). Conclusion: Postpartum women (up to 6 months) had greater fatigability of the lumbopelvic stabilizing muscles and lower physical function than nulligravid women, suggesting core muscle function and fatigability should be assessed after pregnancy and childbirth. The ASLR Fatigue Task could be a clinically useful tool to determine fatigability of the lumbopelvic stabilizing muscles in women postpartum.
- 1 January 2018
- Published by Wolters Kluwer Health in Journal of Women's Health Physical Therapy
- Vol. 42 (3) , 128-138
Open AccessFatigability of the Lumbopelvic Stabilizing Muscles in Women 8 and 26 Weeks Postpartum
Background: Pregnancy and childbirth are associated with lumbopelvic pain and instability. Fatigability of the lumbopelvic stabilizing muscles after childbirth is unknown, and no clinical tests exist to assess this important metric of muscle function. Objectives: To compare fatigability of the lumbopelvic stabilizing muscles in postpartum and nulligravid (control) women using the Active Straight Leg Raise (ASLR) Fatigue Task, and to determine whether fatigability is associated with interrecti distance (IRD), physical function, and pain/disability. Study design: A longitudinal case-control study. Methods: Twenty-nine nulligravid (25.4 ± 9.1 years) and 31 postpartum women (31.4 ± 5.2 years; vaginal delivery n = 18) were tested at 2 time points, 16 weeks apart (postpartum women tested at 8-10 and 24-26 weeks postpartum). Muscular function was assessed with manual muscle testing (MMT), the ASLR test, and a new ASLR Fatigue Task. Other measures included IRD, rectus abdominis thickness, physical activity, and 6-minute walk distance. Results: Postpartum women were 23% more fatigable (P = .028) and were weaker (MMT) (P < .001) than controls up to 26 weeks postpartum. The ASLR Fatigue Task (time-to-failure) was associated with smaller IRD, greater rectus abdominis thickness, higher physical activity levels, greater MMT strength, and further distance walked in 6 minutes (P < .05). Conclusion: Postpartum women (up to 6 months) had greater fatigability of the lumbopelvic stabilizing muscles and lower physical function than nulligravid women, suggesting core muscle function and fatigability should be assessed after pregnancy and childbirth. The ASLR Fatigue Task could be a clinically useful tool to determine fatigability of the lumbopelvic stabilizing muscles in women postpartum.
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (1) , S138-S139
Correlation of BMI to Magnesium Levels in Patients With Preeclampsia [24M]
To determine the relationship between BMI and magnesium blood levels following a 4 or 6 gram bolus of IV magnesium in preeclamptic women. Retrospective chart review from 2005 to 2015 analyzing magnesium levels in preeclamptic women. Patients received IV magnesium bolus (4 or 6 grams) followed by a basal rate of 2 grams/hour. Magnesium levels were then drawn approximately 4 hours after the bolus dose. Magnesium levels from 4.8 to 8.4 mg/dL were considered therapeutic. BMI and labs (creatinine, ALT, AST, platelets) were compared between therapeutic and sub-therapeutic groups. 508 patient charts reviewed; 207 met inclusion criteria. Patients with BMI less than or equal to 30 had fewer sub-therapeutic levels than therapeutic levels (Sub-therapeutic: 38.5%; Therapeutic: 61.5%; P-value less than 0.001). Patients with a BMI less than 30 had more sub-therapeutic levels than therapeutic (Sub-therapeutic: 76%; Therapeutic: 24%; P-value less than 0.001). In patients with BMI greater than 35, there were more patients in the sub-therapeutic group (Sub-therapeutic: 83%; Therapeutic: 17%; P-value 0.024). Creatinine was lower in the sub-therapeutic group compared to therapeutic group (Subtherapeutic: 0.66; Therapeutic: 0.73; P-value: 0.003). ROC curve demonstrated 4 gram magnesium bolus with BMI greater than or equal to 30 likely will not reach a therapeutic level (Sensitivity: 0.84, Specificity: 0.51), nor will 6 gram magnesium bolus with BMI greater than or equal to 35 (Sensitivity: 0.74, Specificity: 0.38). There is an inverse relationship between BMI and blood magnesium levels. When BMI reaches above 30, patients are more likely to be sub-therapeutic than therapeutic.
- 1 May 2017
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 129 (1) , S138-S139
Correlation of BMI to Magnesium Levels in Patients With Preeclampsia [24M]
To determine the relationship between BMI and magnesium blood levels following a 4 or 6 gram bolus of IV magnesium in preeclamptic women. Retrospective chart review from 2005 to 2015 analyzing magnesium levels in preeclamptic women. Patients received IV magnesium bolus (4 or 6 grams) followed by a basal rate of 2 grams/hour. Magnesium levels were then drawn approximately 4 hours after the bolus dose. Magnesium levels from 4.8 to 8.4 mg/dL were considered therapeutic. BMI and labs (creatinine, ALT, AST, platelets) were compared between therapeutic and sub-therapeutic groups. 508 patient charts reviewed; 207 met inclusion criteria. Patients with BMI less than or equal to 30 had fewer sub-therapeutic levels than therapeutic levels (Sub-therapeutic: 38.5%; Therapeutic: 61.5%; P-value less than 0.001). Patients with a BMI less than 30 had more sub-therapeutic levels than therapeutic (Sub-therapeutic: 76%; Therapeutic: 24%; P-value less than 0.001). In patients with BMI greater than 35, there were more patients in the sub-therapeutic group (Sub-therapeutic: 83%; Therapeutic: 17%; P-value 0.024). Creatinine was lower in the sub-therapeutic group compared to therapeutic group (Subtherapeutic: 0.66; Therapeutic: 0.73; P-value: 0.003). ROC curve demonstrated 4 gram magnesium bolus with BMI greater than or equal to 30 likely will not reach a therapeutic level (Sensitivity: 0.84, Specificity: 0.51), nor will 6 gram magnesium bolus with BMI greater than or equal to 35 (Sensitivity: 0.74, Specificity: 0.38). There is an inverse relationship between BMI and blood magnesium levels. When BMI reaches above 30, patients are more likely to be sub-therapeutic than therapeutic.
- Open Access
- 16 July 2012
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 30 (01) , 053-058
Ambulatory Arrhythmia Monitoring in Pregnant Patients with Palpitations
Objective To assess the frequency of rhythm disturbances (RDs) obtained following placement of a Holter monitor or an event loop recorder (ERT) in patients referred to cardiologists. Study Design Ninety-six gravidas were referred to the cardiology clinic for palpitations, syncope, or dizziness and had Holter monitoring or ERT after a baseline electroencephalogram. Arrhythmias were classified by severity. Results Gestational age at referral was 22.6 weeks ± 8.3 days. Sixty-five patients had ERTs performed, and 19 had Holter monitors. Seventy-six percent had benign arrhythmias. In our ERT cohort, history of arrhythmias showed a fourfold increase in serious RD during gestation (odds ratio [OR] 4.7, 95% confidence interval [CI] 1.1 to 20.3, p = 0.01); obesity (body mass index >30) had a fourfold increased risk (OR 4.0, 95% CI 1.0 to 1, p = 0.03). Serious RD did not result in greater chance of cesarean delivery or induction of labor, or a newborn with arrhythmias. Conclusion Most pregnant women with palpitations have benign arrhythmias. ERT appears to be a better method of diagnosis in pregnant women.
- 16 July 2012
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 30 (01) , 053-058
Open AccessAmbulatory Arrhythmia Monitoring in Pregnant Patients with Palpitations
Objective To assess the frequency of rhythm disturbances (RDs) obtained following placement of a Holter monitor or an event loop recorder (ERT) in patients referred to cardiologists. Study Design Ninety-six gravidas were referred to the cardiology clinic for palpitations, syncope, or dizziness and had Holter monitoring or ERT after a baseline electroencephalogram. Arrhythmias were classified by severity. Results Gestational age at referral was 22.6 weeks ± 8.3 days. Sixty-five patients had ERTs performed, and 19 had Holter monitors. Seventy-six percent had benign arrhythmias. In our ERT cohort, history of arrhythmias showed a fourfold increase in serious RD during gestation (odds ratio [OR] 4.7, 95% confidence interval [CI] 1.1 to 20.3, p = 0.01); obesity (body mass index >30) had a fourfold increased risk (OR 4.0, 95% CI 1.0 to 1, p = 0.03). Serious RD did not result in greater chance of cesarean delivery or induction of labor, or a newborn with arrhythmias. Conclusion Most pregnant women with palpitations have benign arrhythmias. ERT appears to be a better method of diagnosis in pregnant women.